TBPH Stock Forecast 2025-2026
Distance to TBPH Price Targets
TBPH Price Momentum
10 Quality Stocks Worth Considering Now
Researching Theravance (TBPH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TBPH and similar high-potential opportunities.
Latest TBPH Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, TBPH has a neutral consensus with a median price target of $13.50 (ranging from $10.00 to $21.00). Currently trading at $9.30, the median forecast implies a 45.2% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 125.8% upside. Conversely, the most conservative target is provided by David Risinger at Leerink Partners, suggesting a 7.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TBPH Analyst Ratings
TBPH Price Target Range
Latest TBPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TBPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $15.00 |
| Aug 6, 2024 | Leerink Partners | David Risinger | Market Perform | Downgrade | $10.00 |
| Aug 6, 2024 | TD Cowen | Marc Frahm | Hold | Maintains | $9.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $15.00 |
| May 29, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $20.00 |
| May 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $20.00 |
| Apr 12, 2024 | BTIG | Julian Harrison | Buy | Initiates | $21.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $20.00 |
| May 9, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $20.00 |
| Feb 28, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $19.00 |
| Nov 17, 2022 | SVB Leerink | David Risinger | Outperform | Maintains | $14.00 |
| Nov 8, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $19.00 |
| Jul 25, 2022 | Morgan Stanley | Vikram Purohit | Underweight | Maintains | $10.00 |
| May 23, 2022 | SVB Leerink | Outperform | Initiates | $0.00 | |
| Mar 2, 2022 | Morgan Stanley | Underweight | Maintains | $11.00 | |
| Feb 24, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $12.00 |
| Nov 5, 2021 | JP Morgan | Anupam Rama | Neutral | Upgrade | $12.00 |
| Sep 16, 2021 | Morgan Stanley | Vikram Purohit | Underweight | Maintains | $10.00 |
Theravance Biopharma Inc. (TBPH) Competitors
The following stocks are similar to Theravance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Theravance Biopharma Inc. (TBPH) Financial Data
Theravance Biopharma Inc. has a market capitalization of $464.53M with a P/E ratio of 0.0x. The company generates $64.38M in trailing twelve-month revenue with a -87.6% profit margin.
Revenue growth is +6.8% quarter-over-quarter, while maintaining an operating margin of -49.1% and return on equity of -29.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Theravance Biopharma Inc. (TBPH) Business Model
About Theravance Biopharma Inc.
Develops innovative medicines for respiratory diseases.
Theravance Biopharma generates revenue through the discovery, development, and commercialization of new pharmaceutical products, focusing on inhalation therapies and small molecule drugs. The company collaborates with other pharmaceutical firms and research organizations to optimize its research and expand its market presence.
Headquartered in George Town, Cayman Islands, with operations in the United States, Theravance Biopharma is dedicated to addressing unmet clinical needs, particularly in chronic obstructive pulmonary disease (COPD) and other serious illnesses, to improve patient outcomes globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
97
CEO
Mr. Rick E. Winningham M.B.A.
Country
United States
IPO Year
2014
Website
www.theravance.comTheravance Biopharma Inc. (TBPH) Latest News & Analysis
TBPH's Q4 earnings met estimates, with sales slightly surpassing expectations, driven by increased collaboration revenues from Viatris.
TBPH's earnings meeting estimates and sales exceeding expectations indicate stable performance, while rising collaboration revenues from Viatris signal growth potential, positively influencing investor sentiment.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will host its Q4 2024 Earnings Conference Call on February 26, 2025, at 5:00 PM ET. Key executives will participate in the call.
Theravance Biopharma's upcoming earnings call will provide insights into financial performance, strategic direction, and potential market impact, influencing stock valuation and investor sentiment.
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
1 month agoTheravance Biopharma reported Q4 2024 net sales of YUPELRI at $66.7M, up 10% YoY, and FY 2024 at $238.6M, up 8%. TRELEGY sales reached $3.46B, triggering a $50M milestone. Cash at $88M.
Record net sales for YUPELRI and significant TRELEGY milestones indicate strong revenue growth for Theravance Biopharma, enhancing its financial stability and attractiveness to investors.
Theravance Biopharma (TBPH) reported a quarterly loss of $0.05 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.03 per share in the same quarter last year.
Theravance Biopharma's quarterly loss aligns with expectations, indicating stability despite a year-over-year decline. Market sentiment may remain cautious as the company continues to report losses.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen Health Care Conference on March 4 at 11:50 am EST and will hold in-person meetings with investors. A webcast will be available.
Theravance Biopharma's conference presentation could indicate upcoming developments or financial performance insights, influencing investor sentiment and stock valuation.
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
1 month agoTheravance Biopharma, Inc. (NASDAQ: TBPH) will report Q4 and full year 2024 results on February 26, 2025, after market close, followed by a conference call at 5:00 pm EST.
Theravance Biopharma's upcoming financial results and business update could significantly impact stock performance and investor sentiment, influencing trading decisions in the biotech sector.
Frequently Asked Questions About TBPH Stock
What is Theravance Biopharma Inc.'s (TBPH) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Theravance Biopharma Inc. (TBPH) has a median price target of $13.50. The highest price target is $21.00 and the lowest is $10.00.
Is TBPH stock a good investment in 2025?
According to current analyst ratings, TBPH has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TBPH stock?
Wall Street analysts predict TBPH stock could reach $13.50 in the next 12 months. This represents a 45.2% increase from the current price of $9.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Theravance Biopharma Inc.'s business model?
Theravance Biopharma generates revenue through the discovery, development, and commercialization of new pharmaceutical products, focusing on inhalation therapies and small molecule drugs. The company collaborates with other pharmaceutical firms and research organizations to optimize its research and expand its market presence.
What is the highest forecasted price for TBPH Theravance Biopharma Inc.?
The highest price target for TBPH is $21.00 from Julian Harrison at BTIG, which represents a 125.8% increase from the current price of $9.30.
What is the lowest forecasted price for TBPH Theravance Biopharma Inc.?
The lowest price target for TBPH is $10.00 from David Risinger at Leerink Partners, which represents a 7.5% increase from the current price of $9.30.
What is the overall TBPH consensus from analysts for Theravance Biopharma Inc.?
The overall analyst consensus for TBPH is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are TBPH stock price projections?
Stock price projections, including those for Theravance Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
